Clinical Performance of the Histidine Rich Protein 2 (HRP2) Highly Sensitive Rapid Diagnostic Test (HS-RDT) for Malaria Diagnosis in Pregnant Women in Papua New Guinea
Clinical Performance of the HRP2 HS-RDT for Malaria Diagnosis in Pregnant Women in Papua New Guinea
Sponsor: Burnet Institute
This observational or N/A phase trial investigates Diagnoses Disease and Plasmodium Falciparum Malaria and is currently ongoing. Burnet Institute leads this study, which shows 7 recorded versions since 2018 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Unknown
-
Jul 2024 — Sep 2024 [monthly]
Unknown
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status
-
Apr 2020 — Jan 2021 [monthly]
Unknown Status
Status: Not Yet Recruiting → Unknown Status
-
Jun 2018 — Apr 2020 [monthly]
Not Yet Recruiting
▶ Show 2 earlier versions
-
Apr 2018 — Jun 2018 [monthly]
Not Yet Recruiting
Phase: NA → None
-
Mar 2018 — Apr 2018 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Burnet Institute
- Foundation for Innovative New Diagnostics, Switzerland
- Papua New Guinea Institute of Medical Research
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.